Home Featured Page 260

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

COMPASS Pathways launches new podcast “Everyone has a story: talking about...

Comparing Psilocybin Mushroom Bruising with Trichoderma Infection

PT250 – Matt Ball – New Frameworks For Schizophrenia, Dissociation, and...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and...

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in...

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And...

MindMed Included in FTSE Russell 3000® Index

Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves...

Psychedelic Treatment for Eating Disorder Recovery

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

COMPASS Pathways launches new podcast “Everyone has a story: talking about...

Comparing Psilocybin Mushroom Bruising with Trichoderma Infection

PT250 – Matt Ball – New Frameworks For Schizophrenia, Dissociation, and...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and...

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in...

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And...

MindMed Included in FTSE Russell 3000® Index

Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves...

Psychedelic Treatment for Eating Disorder Recovery

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY